Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies

ECCO'20 Vienna

Year: 2020
Authors:

M. Rutka, K. Farkas, D. Pigniczki, K. Szántó, B. Anita, R. Bor, A. Fábián, Z. Szepes, F. Nagy, T. Molnár

University of Szeged, Department of Medicine I, Szeged, Hungary

P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort

ECCO'20 Vienna

Year: 2020
Authors:

M. TRUYENS1,2,3, J. Geldof1, G. Dewitte1, E. Glorieus1, G. Varkas2,4, D. Elewaut2,4, T. Lobaton Ortega1,3

1University Hospital Ghent, Gastroenterology, Ghent, Belgium, 2Ghent University, VIB center for Inflammation Research, Ghent, Belgium, 3Ghent University, IBD research unit, Department of Internal Medicine and Pediatrics, Ghent, Belgium, 4Host-Microbiota Interaction Lab and Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent, Belgium

P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study

ECCO'20 Vienna

Year: 2020
Authors:

C. Rayer1, X. Roblin2, D. Laharie3, B. Caron4, M. Flamant5, M. Dewitte1, M. Fumery6, S. Viennot7, A. Bourreille8, B. Pariente9, L. Siproudhis1, L. Peyrin-Biroulet10, G. Bouguen1

1CHU Pontchaillou, Department of Gastroenterology, Rennes, France, 2CHU Saint-Etienne, Gastroenterology, Saint-Etienne, France, 3CHU Bordeaux, Gastroenterology, Bordeaux, France, 4CHU Strasbourg, Department of Gastroenterology, Strasbourg, France, 5Clinique Jules Vernes, Gastroenterology, Nantes, France, 6CHU Amiens, Department of Gastroenterology, Amiens, France, 7CHU Caen, Department of Gastroenterology, Caen, France, 8CHU Nantes, Gastroenterology, Nantes, France, 9CHU Lille, Department of Gastroenterology, Lille, France, 10CHU Nancy, Department of Gastroenterology, Nancy, France

P666 Neutropenia in inflammatory bowel disease patients on TNF inhibitors: A single-centre, retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

D. AlAskar, A. Mais, E. Al Sulais, T. Alameel

King Fahad Specialist Hospital Dammam, Medicine, Dammam, Saudi Arabia

P667 Combined therapy of perianal fistulas with autologous adipose-derived stem cells

ECCO'20 Vienna

Year: 2020
Authors:

A. Surowiecka, M. Łodyga, M. Durlik, R. Grażyna

Central Clinical Hospital of the Ministry of Interior in Warsaw MSWiA, Clinical Department of Gastroenterological Surgery and Transplantation, Warsaw, Poland

P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

B. Barberio, F. Zingone, R. D’Incà, C. Marinelli, M.C. Maccarone, A. Gubbiotti, L. Cingolani, G. Lorenzon, M. Ghisa, E.V. Savarino

University of Padua, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital

ECCO'20 Vienna

Year: 2020
Authors:

L. Ramos Lopez1, J. Ramos Rodríguez2, R. De La Barreda1, F. Guitierrez2, G.J. Nazco Casariego2, I. Alonso Abreu1, M. Carrillo Palau1, E. Quintero1

1Hospital Universitario De Canarias, Gastroenterology, Santa Cruz De Tenerife, Spain, 2Hospital Universitario De Canarias, Pharmacy, Santa Cruz De Tenerife, Spain

P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis

ECCO'20 Vienna

Year: 2020
Authors:

K. Bąk-Drabik1, J. Duda-Wrońska2, D. Dąbrowska-Piechota2, P. Adamczyk3

1Department of Peadiatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia- Katowice, Zabrze, Poland, 2Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice Students Association, Department of Peadiatrics, Zabrze, Poland, 3Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Department of Peadiatrics, Katowice, Poland

P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study

ECCO'20 Vienna

Year: 2020
Authors:

A. Madarame1, H. Kinoshita1, T. Yamaguchi1, Y. Izumi1, Y. Nishikawa1, S. Shonai1, M. Tatsuno1, Y. Ishii1, K. Yaguchi1, Y. Nakamori1, A. Ikeda1, K. Araki1, A. Hirayama1, T. Ogashiwa1, A. Fuji1, R. Suzuki2, H. Kimura1, R. Kunisaki1

1Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 2Kannai Suzuki Clinic, Inflammatory Bowel Disease Centre, Yokohama, Japan

P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?

ECCO'20 Vienna

Year: 2020
Authors:

A.J. Walsh, L. Matini, R. Kantschuster, M. Lepetyukh, D. Simadibrata, G. Collins, J. Wilson, M. Hussain, A. Tarafdar, O. Brain, R. Palmer, T. Ambrose, J. Satsangi, S.P.L. Travis

Oxford University Hospitals NHS Foundation Trust and Oxford AHSN, Translational Gastroenterology Unit, Oxford, UK

P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum

ECCO'20 Vienna

Year: 2020
Authors:

T. Amano, S. Shinzaki, T. Tashiro, Y. Otake, M. Tani, T. Yoshihara, S. Iwatani, Y. Tsujii, T. Inoue, Y. Hayashi, H. Iijima, T. Takehara, Osaka Gut Forum

Osaka University Graduate School of Medicine, Gastroenterology and Hepatology, Suita, Japan

P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week

ECCO'20 Vienna

Year: 2020
Authors:

M.T. Diz Lois Palomares1, Á. Porta Sánchez2, L. Elberdin Pazos2, B. González Conde1, M. Outeda Macías2, M.T. Vázquez Rey1, A. Guerrero Montañés1, E. Estévez Prieto1

1A Coruña Universitary Hospital, Gastroenterology Unit, A Coruña, Spain, 2A Coruña Universitary Hospital, Pharmacy Unit, A Coruña, Spain

P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: A multicentre prospective observational comparative study

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, X. Hebuterne2, M. Raith3, A. Amiot4, C. Tanasa Stefanescu1, D. Laharie5, X. Roblin6, A. Bourreille7, S. Nancey8, N. Sabbah9, L. Peyrin Biroulet10

1Hopital Beaujon, Service de Gastroentérologie,MICI et Assistance Nutritive, Clichy, France, 2Hopital Archet, Service de Gastroentérologie et Nutrition Clinique, Nice, France, 3CTMA, Project Manajer, Paris, France, 4Hopital Henri Mondor, Service de Gastroentérologie, Creteil, France, 5Hopital Haut-Léveque, Service d’Hépato-Gastroentérologie, Bordeaux, France, 6Hopital Bellevue, Service de Gastroentérologie, Saint Etienne, France, 7CHU Hotel-Dieu, Institut des maladies de l’appareil digestif, Nantes, France, 8Hopital Lyon Sud, Service d’hépatogastroentérologie, Lyon, France, 9CTMA, Chief Operating Officier, Paris, France, 10CHU Nancy, Hépato-Gastro-Entérologie, Nancy, France

P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients

ECCO'20 Vienna

Year: 2020
Authors:

K. Farkas1, K.J. Szántó1, D. Kata2, I. Földesi2, T. Ferenci3, M. Rutka1, D. Pigniczki1, R. Bor1, A. Fábián1, Z. Szepes1, F. Nagy1, T. Molnár1

1First Department of Medicine, University of Szeged, Szeged, Hungary, 2Department of Laboratory Medicine, University of Szeged, Szeged, Hungary, 3Physiological Controls Research Center, Óbuda University, Szeged, Hungary

P677 It’s time to grow up: what is it like to transition from the paediatric to adult inflammatory bowel disease service?

ECCO'20 Vienna

Year: 2020
Authors:

P. Keightley1,2, R. Prematunga1, P. Hoffmann3, K. Subramaniam2,4

1Canberra Health Services, Mental Health, Justice Health, Alcohol and Drug Services, Canberra, Australia, 2Australian National University, Australian National University Medical School, Canberra, Australia, 3Canberra Health Services, Acute Allied Health Psychology Department, Canberra, Australia, 4Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia

P678 Effect of accelerated infliximab induction on short-term outcomes of paediatric acute severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

M.B. Coronel-Arismendi, G. Pujol Muncunill, B. Minguez-Rodríguez, S. Feo-Ortego, L.N. Guevara-Caviedes, V. Vila-Miravet, F.J. Martin De Carpi

Hospital Sant Joan de Déu, Unit for the Comprehensive Care of Pediatric Inflammatory Bowel Disease, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Esplugues de Llobregat, Spain

P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?

ECCO'20 Vienna

Year: 2020
Authors:

A. Cerpa Arencibia, C. Suarez Ferrer, J. Poza Cordón, E. Martín Arranz, L. Ramírez, M.D. Martín Arranz

Hospital La Paz, Gastroenterology, Madrid, Spain

P681 Efficacy of vedolizumab for the prevention of postoperative recurrence in Crohn’s disease: Data from clinical practice from the ENEIDA registry

ECCO'20 Vienna

Year: 2020
Authors:

M. Mañosa Ciria1, E. Hinojosa2, A. Carbajo3, J. Castro4, N. Manceñido5, M. Calvo6, A. Núñez Alonso7, J. P Gisbert8, P. Nos9, J. Guardiola10, E. Sainz11, E. Sánchez-Rodríguez12, F. Cañete1, M. Calafat1, E. Domènech1, Eneida Registry

1Hospital Universitari Germans Trias I Pujol, Department of Gastroenterology CIBERehd, IBD Unit, Badalona, Spain, 2Hospital de Manises, Gastroenterology, Manises, Spain, 3Hospital Rio Hortega, Gastroenterology, Valladolid, Spain, 4Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain, 5Hospital Infanta Sofia, Gastroenterology, Madrid, Spain, 6Hospital Puerta de Hierro, Gastroenterology, Madrid, Spain, 7Hospital de Salamanca, Gastroenterology, Salamanca, Spain, 8Hospital La Princesa, Gastroenterology, Madrid, Spain, 9Hospital La Fe, Gastroenterology, Valencia, Spain, 10Hospital de Bellvitge, Gastroenterology, Barcelona, Spain, 11Althaia, Gastroenterology, Manresa, Spain, 12Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain

P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Yarur1, M. Chiorean2, J. Zhang3, W. Reinisch4, S. Vermeire5, J. Panés6, L. Peyrin-Biroulet7, B.E. Sands8, C.H. Cabell3, S.U. Naik3, W.J. Sandborn9

1Medical College of Wisconsin, n/a, Milwaukee, USA, 2Virginia Mason Medical Center, n/a, Seattle, USA, 3Arena Pharmaceuticals, n/a, San Diego, USA, 4Medical University of Vienna, n/a, Vienna, Austria, 5University Hospitals Leuven, n/a, Leuven, Belgium, 6Hospital Clinic of Barcelona- DIBAPS- CIBERehd, n/a, Barcelona, Spain, 7Lorraine University, Department of Gastroenterology- INSERM U954, Vandoeuvre-lès-Nancy, France, 8Icahn School of Medicine at Mount Sinai, n/a, New York, USA, 9University of California San Diego, n/a, La Jolla, USA